BACKGROUND: Percutaneous coronary intervention (PCI) of saphenous vein graft (SVG) is associated with frequent postprocedural enzyme elevation and late cardiac events. New strategies are proposed to minimize distal embolization and to improve the outcome of patients treated with stenting for SVG lesions. The objectives of the current study were to examine direct stenting (DS) strategy of PCI in SVG lesions and its effects on creatine-kinase (CK) release, major adverse cardiac events (MACE), and late outcome when compared to conventional stenting (CS). METHODS: A consecutive series of 527 patients treated with stent implantation for SVG stenosis was analyzed. In this cohort, 170 patients with 229 lesions were treated with DS and 357 patients with 443 lesions were treated with CS. The inhospital and 12-month follow-up events were recorded and reported. RESULTS: Baseline clinical and postprocedural angiographic characteristics were similar between the 2 groups except for higher preprocedural prevalence of thrombus-containing lesions in the DS group. Patients in the DS group had less CK-MB release (P <.001), and less non-Q-wave myocardial infarction (P =.024). Multivariate analysis detected unstable angina (odds ratio [OR] = 1.8, P =.03) as a correlate for non-Q-wave MI; DS was inversely associated with non-Q-wave myocardial infarction (OR = 0.65, P =.04). At 1 year, the target lesion revascularization-MACE was significantly lower in the DS group (P =.021). Multivariate analysis showed that DS (OR = 0.47, P =.007) was associated with reduction of the target lesion revascularization-MACE. CONCLUSIONS: When feasible, DS may be the best approach for treating SVG stenosis.
BACKGROUND: Percutaneous coronary intervention (PCI) of saphenous vein graft (SVG) is associated with frequent postprocedural enzyme elevation and late cardiac events. New strategies are proposed to minimize distal embolization and to improve the outcome of patients treated with stenting for SVG lesions. The objectives of the current study were to examine direct stenting (DS) strategy of PCI in SVG lesions and its effects on creatine-kinase (CK) release, major adverse cardiac events (MACE), and late outcome when compared to conventional stenting (CS). METHODS: A consecutive series of 527 patients treated with stent implantation for SVG stenosis was analyzed. In this cohort, 170 patients with 229 lesions were treated with DS and 357 patients with 443 lesions were treated with CS. The inhospital and 12-month follow-up events were recorded and reported. RESULTS: Baseline clinical and postprocedural angiographic characteristics were similar between the 2 groups except for higher preprocedural prevalence of thrombus-containing lesions in the DS group. Patients in the DS group had less CK-MB release (P <.001), and less non-Q-wave myocardial infarction (P =.024). Multivariate analysis detected unstable angina (odds ratio [OR] = 1.8, P =.03) as a correlate for non-Q-wave MI; DS was inversely associated with non-Q-wave myocardial infarction (OR = 0.65, P =.04). At 1 year, the target lesion revascularization-MACE was significantly lower in the DS group (P =.021). Multivariate analysis showed that DS (OR = 0.47, P =.007) was associated with reduction of the target lesion revascularization-MACE. CONCLUSIONS: When feasible, DS may be the best approach for treating SVG stenosis.
Authors: Faisal Latif; Lauren Uyeda; Robert Edson; Deepak L Bhatt; Steven Goldman; David R Holmes; Sunil V Rao; Kendrick Shunk; Kul Aggarwal; Barry Uretsky; Islam Bolad; Khaled Ziada; Edward McFalls; Anand Irimpen; Huu Tam Truong; Scott Kinlay; Vasilios Papademetriou; Raghava S Velagaleti; Bavana V Rangan; Kreton Mavromatis; Mei-Chiung Shih; Subhash Banerjee; Emmanouil S Brilakis Journal: Circ Cardiovasc Interv Date: 2020-02-05 Impact factor: 6.546
Authors: Rafał Januszek; Zbigniew Siudak; Artur Dziewierz; Tomasz Rakowski; Dariusz Dudek; Stanisław Bartuś Journal: Arch Med Sci Date: 2019-01-30 Impact factor: 3.318
Authors: Theodor Baars; Thomas Konorza; Philipp Kahlert; Stefan Möhlenkamp; Raimund Erbel; Gerd Heusch; Petra Kleinbongard Journal: Cardiovasc Diabetol Date: 2013-01-10 Impact factor: 9.951
Authors: Patrick Horn; Theodor Baars; Philipp Kahlert; Christian Heiss; Ralf Westenfeld; Malte Kelm; Raimund Erbel; Gerd Heusch; Petra Kleinbongard Journal: PLoS One Date: 2015-04-27 Impact factor: 3.240